LC
NVO

Lavaca Capital’s Novo Nordisk NVO Stock Holding History

Lavaca Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Sell
440
-400
-48% -$17.2K ﹤0.01% 270
2026
Q1 		$30.9K Hold
840
– – 0.01% 196
2025
Q4 		$42.7K Hold
840
– – 0.01% 182
2025
Q3 		$46.6K Hold
840
– – 0.01% 170
2025
Q2 		$58K Hold
840
– – 0.02% 156
2025
Q1 		$58.3K Sell
840
-88
-9% -$7.27K 0.02% 146
2024
Q4 		$79.8K Buy
+928
New +$100K 0.03% 148
2019
Q2 		– Sell
-2,256
Closed -$59K – 257
2019
Q1 		$59K Hold
2,256
– – 0.05% 142
2018
Q4 		$52K Buy
+2,256
New +$50.1K 0.05% 127

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Lavaca Capital's NVO Position: Q2 2026 in Review

Lavaca Capital reduced its Novo Nordisk (NVO) stake by 48% in Q2 2026, selling an estimated $17.2K and leaving 440 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

Lavaca Capital first reported a position in NVO in Q4 2018 and has held it in 9 quarters since. The position peaked at $79.8K in Q4 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Lavaca Capital held 440 shares of Novo Nordisk worth $21.1K as of Q2 2026.
  • Lavaca Capital sold 400 Novo Nordisk shares in Q2 2026, an estimated $17.2K.
  • Novo Nordisk made up ﹤0.01% of Lavaca Capital's portfolio in Q2 2026, its #270 holding.
  • Lavaca Capital first reported a position in Novo Nordisk in Q4 2018 and has held it in 9 quarters since.
  • Lavaca Capital's Novo Nordisk position peaked at $79.8K in Q4 2024.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Lavaca Capital's 13F filing for Q2 2026, filed 14 Aug 2026.